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Low oxygen pressure (hypoxia) plays an important role in stimulating angiogenesis; there are, 
however, few studies to prepare hypoxia-mimicking tissue engineering scaffolds. Mesoporous 
bioactive glass (MBG) has been developed as scaffolds with excellent osteogenic properties for 
bone regeneration. Ionic cobalt (Co) is established as a chemical inducer of hypoxia-inducible 
factor (HIF)-1α, which induces hypoxia-like response. The aim of this study was to develop 
hypoxia-mimicking MBG scaffolds by incorporating ionic Co2+ into MBG scaffolds and investigate 
if the addition of Co2+ ions would induce a cellular hypoxic response in such a tissue engineering 
scaffold system. The composition, microstructure and mesopore properties (specific surface area, 
nano-pore volume and nano-pore distribution) of Co-containing MBG (Co-MBG) scaffolds were 
characterized and the cellular effects of Co on the proliferation, differentiation, vascular endothelial 
growth factor (VEGF) secretion, HIF-1α expression and bone-related gene expression of human 
bone marrow stromal cells (BMSCs) in MBG scaffolds were systematically investigated. The 
results showed that low amounts of Co (< 5%) incorporated into MBG scaffolds had no significant 
cytotoxicity and that their incorporation significantly enhanced VEGF protein secretion, HIF-1α 
expression, and bone-related gene expression in BMSCs, and also that the Co-MBG scaffolds 
support BMSC attachment and proliferation. The scaffolds maintain a well-ordered mesopore 
channel structure and high specific surface area and have the capacity to efficiently deliver 
antibiotics drugs; in fact, the sustained released of ampicillin by Co-MBG scaffolds gives them 
excellent anti-bacterial properties. Our results indicate that incorporating cobalt ions into MBG 
scaffolds is a viable option for preparing hypoxia-mimicking tissue engineering scaffolds and 
significantly enhanced hypoxia function. The hypoxia-mimicking MBG scaffolds have great 
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potential for bone tissue engineering applications by combining enhanced angiogenesis with already 
existing osteogenic properties. 
 




The treatment of many bone defects, especially large bone defects due to trauma, infections, tumors 
or genetic malformations, represents a major challenge for clinicians [1,2]. Autologous bone 
grafting is considered the most effective treatment; in practice, however, this approach is limited by 
insufficient amount of donor tissue, coupled with donor site morbidity. Allogeneic or xenogeneic 
bone grafts, on the other hand, have obvious clinical limitations due to immunological reactions in 
the host recipient. Bone tissue engineering approaches has come into focus as an alternative source 
for bone regeneration [3-5] as a substitute for bone grafts in order to repair defects and restore 
normal function [6]. This approach consists of applying a supportive matrix (a scaffold) to support 
osteogenic cells and bioactive molecules for bone reconstruction. A critical problem, implicit in 
using this approach, is that the nutrient supply and cell viability, at the centre of the scaffold, is 
severely hampered since the diffusion distance of nutrients and oxygen for cell survival is limited to 
150–200µm [7]. Indeed, studies have shown that tissue engineered products formed tissue layers no 
thicker than 5 mm on the scaffold surface, and that in the centre of the scaffold, cell density tends to 
be low and necrosis may occur [7]. 
Low oxygen pressure (hypoxia) in vivo plays a pivotal role in coupling angiogenesis with 
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osteogenesis via progenitor cell recruitment, differentiation and angiogenesis [8-11]. Hypoxia 
activates a series of angiogneic processes mediated by the hypoxia inducing factor-1a (HIF-1α) 
transcription factor. HIF-1α initiates the expression of a number of genes associated with tissue 
regeneration and skeletal tissue development and has been shown to enhanced fracture repair. 
Hypoxia can the mimicked artificially by stabilizing HIF-1α expression , such as by the application 
of Co2+ ions, and has been suggested as a potential strategy to promote neovascularization [8,12,13]. 
Co is an essential element in human physiology and an integral part of B12, a vitamine the human 
body is unable to manufacture. Ionic Co2+ is known to chemically induce HIF-1α to promote a 
hypoxia-like response. Cells adapt to hypoxia by expressing a number of genes that are related to 
angiogenesis, mobility, and glucose metabolism, all via the HIF-1α pathway [14].  
Mesoporous bioactive glass (MBG) has attracted significant attention for bone tissue engineering in 
the past several years [15-19]. Compared with non-mesopore bioactive glass (NBG) MBG has 
significantly improved specific surface area and nanopore volume, which is evidenced by greatly 
enhanced in vitro bioactivity and degradation [15,20-22] As a bioactive material, MBG has great 
potential for bone tissue engineering and drug delivery applications [23-25]. Cobalt ions are a 
well-established chemical inducer of HIF-1α which elicits a hypoxia-like response. It is expected 
that Co ions released from scaffolds could inactivate HIF-specific prolyl hydroxylase and 
consequently stabilize HIF-1α in a normoxic environment [26]. We hypothesized that MBG 
scaffolds with controllable Co ion release could mimic hypoxic condition and induce the coupling 
of osteogenesis and angiogenesis, which would be of great interest for applications in bone tissue 
engineering. Previously, although Azevedo, et al. prepared Co-containing bioactive glasses particles 
by high temperature melt method, however, they did not investigate whether Co ion release from 
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biomaterials could induce a hypoxia function [27]. To our best knowledge, no previous studies have 
prepared hypoxia-mimicking tissue engineering scaffolds. Therefore, the aims of this study were to 
prepare Co-containing MBG scaffolds and investigate whether the addition of Co could induce a 
hypoxia function in tissue engineering scaffold system. For this aim, the effect of Co on the 
physicochemical property of MBG scaffolds, and the proliferation, differentiation, VEGF secretion, 
HIF-1α expression, and bone-related gene expression of BMSCs in the scaffolds were 
systematically studied. The drug-delivery properties and anti-bacterial functions of the 
manufactured Co-MBG scaffolds are also investigated with respect to bone tissue engineering 
applications. 
 
2. Materials and Methods 
2.1. Preparation and characterization of porous Co-MBG scaffolds 
Porous cobalt-containing mesopore-bioglass (Co-MBG) scaffolds were prepared by incorporating 
Co (molar: 2 and 5%) into MBG to replace parts of calcium (Ca) using co-templates of nonionic 
block polymer P123 (EO20-PO70-EO20) and polyurethane sponges. P123 is used to produce 
mesoporous structures (mesopore size: several nanometers) and polyurethane sponges are used to 
create large pores (large pore size: several hundred micrometers) as described in our previous 
publications [28,29]. To prepare MBG scaffolds containing of 2% cobalt, typically, 12 g of P123 
(Mw=5800, Aldrich), 20.1 g of tetraethyl orthosilicate (TEOS, 98%), 3.64 g of Ca(NO3)2·4H2O, 
0.31 g of CoCl2 (Aldrich), 2.19 g of triethyl phosphate (TEP, 99.8%) and 3 g of 0.5 M HCl were 
dissolved in 180 g of ethanol (Co/Ca/P/Si/ = 2/13/5/80, molar ratio, named 2Co-MBG) and stirred 
at room temperature for 1 day. The polyurethane sponges (20ppi) were cleaned and completely 
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immersed into this solution for 10 min, then transferred to a Petri dish to allow evaporating at room 
temperature for 12 h. This procedure was repeated for 3 times. Once the samples were completely 
dry, they were calcined at 700oC for 5 h yielding the 2Co-MBG scaffolds. MBG scaffolds without 
cobalt (Co/Ca/P/Si/ = 0/15/5/80, molar ratio, named: MBG) and with 5% cobalt (Co/Ca/P/Si/ = 
5/10/5/80, molar ratio named: 5Co-MBG) were prepared by the same method except for their Co 
and Ca contents.  
The large-pore structure, surface morphology, and inner microstructure of the calcined Co-MBG 
scaffolds were characterized by scanning electron microscopy (SEM), energy dispersive 
spectrometer (EDS), small-angle X-ray diffraction (XRD) and transmission electron microscopy 
(TEM). Brunauer-Emmett-Teller (BET) and Barret-Joyner-Halenda (BJH) analyses were used to 
determine the specific surface area, the nano-pore size distribution and the nano-pore volume by N2 
adsorption-desorption isotherms. 
 
2.2. Ion release of Co-MBG scaffolds in DMEM 
To investigate the ion release and mineralization of Co-MBG scaffolds, Co-MBG scaffolds (5×5×5 
mm) were soaked in Dulbecco’s Modified Eagle’s Medium (DMEM) at 37°C for 1, 3 and 7d, and 
the ratio of the solution volume to the scaffold mass was 200 mL/g. The concentrations of Co2+, 
SiO44-, Ca2+ and PO43- ions in the DMEM were determined by inductive coupled plasma atomic 
emission spectrometry (ICP-AES).  
 
2.3. Morphology and proliferation of BMSCs on Co-MBG scaffolds 
Isolation and culture of BMSCs were conducted following previously published protocols [30,31].  
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Bone marrow aspirates were obtained from patients (mean age, 60 years) undergoing elective knee 
and hip replacement surgery. Informed consent was given by all patients involved and the research 
protocol had been approved by the Human Ethics Committees of Queensland University of 
Technology and The Prince Charles Hospital.   
BMSCs were cultured on 5×5×5 mm scaffolds placed in 96-well culture plates, at an initial density 
of 1×105 cells/scaffold. The cells were cultured for 1 and 7 days in DMEM culture medium (GIBCO) 
supplemented with 10% FCS, after which the scaffolds were removed from the culture wells, rinsed 
in PBS, and then fixed with 2.5% glutaraldehyde in PBS for 1 hr. The fixative was removed by 
washing with buffer containing 4% (w/v) sucrose in PBS and post fixed in 1% osmium tetroxide in 
PBS. Then the cells were dehydrated in a graded ethanol series (50, 70, 90, 95 and 100%) and 
hexamethyldisilizane (HMDS). The specimens were coated with gold and the morphological 
characteristics of the attached cells determined using SEM. 
To assess cell proliferation, an MTT assay was performed by adding 0.5 mg/mL of MTT solution 
(Sigma-Aldrich) to each scaffold and incubated 37ºC to form formazan crystals. After 4 h, the 
media was removed and the formazan solubilized with dimethyl sulfoxide (DMSO). The 
absorbance of the formazan-DMSO solution was read at 495 nm on a plate reader. Results were 
expressed as the absorbance reading from each well minus the optical density value of blank wells. 
 
2.4. Alkaline phosphatase (ALP) activity of BMSCs on Co-MBG scaffolds 
Osteogenic differentiation was assessed by measuring a time course of alkaline phosphatase (ALP) 
activity of BMSCs grown on the various scaffold types. Scaffolds were placed into 24-well plastic 
culture plates and seeded with 1x105 BMSCs per scaffold. The cells were incubated at 37ºC in 5% 
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CO2 for 7 days and the medium changed every 3 days. On day 7, the samples were removed and 
ALP activity was measured. The scaffolds were irrigated with PBS three times to remove as much 
residual serum as possible and then 0.5 mL of 0.02% Triton® X-100 were placed on the scaffold 
sample to dissolve the cells. The solution was transferred into a 1.5 mL tube, and sonicated after 
which the samples were centrifuged at 14,000 rpm for 15 min at 4°C. The supernatant transferred to 
fresh 1.5 mL tubes to which 100 µL 1 mol/L Tris-HCl, 20 μL 5 mmol/L MgCl2, and 20 μL 5 
mmol/L p-nitrophenyl phosphate was added. After 30 min incubation at 37°C the reaction was 
stopped by the addition of 50 μL of 1N NaOH. Using p-nitrophenol as a standard, the optical 
density was measured at 410 nm with a spectrophotometer. The ALP activity was expressed as the 
changed optical density (OD) value divided by the reaction time and the total protein quantity as 
measured by the BCA Protein assay kit (Thermo Scientific, Melbourne, Australia). 
 
2.5. VEGF secretion and HIF-1α expression 
To measure the VEGF secretion and HIF-1α expression of BMSCs on Co-MBG scaffolds, the 
scaffolds were transferred into 24-well plastic culture plates and a total of 1x106 BMSCs were 
placed onto each scaffold. The cells were incubated at 37ºC in 5% CO2 for 7 days and the medium 
changed every 3 days. The supernatant was collected and the release of VEGF expression was 
quantified using ELISA assay kits (R&D Systems Inc., Bio-Scientific Pty. Ltd., NSW, Australia) 
according to the manufacturer’s instruction. The test was performed in triplicates and results were 
expressed as the amount (pg) of VEGF in per μl supernatant. 
For direct detection of the HIF-1α protein, western blot analysis was performed. Briefly, after 
seeded onto scaffold for one week, whole cell lysates were obtained. 10µg protein from each 
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sample was separated on SDS-PAGE gels. The protein was then transferred onto a nitrocellulose 
membrane (Pall Corporation, East Hills, NY, USA) and blocked in 5% non-fat milk. The 
membranes were incubated with primary antibodies against HIF-1α (1:1000, mouse anti-human, 
Novus Biologicals, Sapphire Bioscience Pty. Ltd., NSW, Australia) and α-tubulin (1:5000, rabbit 
anti-human, Abcam, Sapphire Bioscience Pty. Ltd., NSW, Australia) overnight at 4 oC. The 
membranes were washed three times in TBS-Tween buffer, and then incubated with 
anti-mouse/rabbit HRP conjugated secondary antibodies at 1:2000 dilutions for 1hr. The protein 
bands were visualized using the SuperSignal West Femto Maximum Sensitivity Substrate (Thermo 
Fisher Scientific, VIC, Australia) and exposed on X-ray film (Fujifilm, Stafford, QLD, Australia).  
 
2.6. Reserve transcription and real-time quantitative RT-PCR analysis  
The osteogenic differentiation of BMSCs on Co-MBG scaffolds was further assessed by real-time 
quantitative RT-PCR (RT-qPCR) to measure the mRNA expression of VEGF and osteocalcin 
(OCN). Scaffolds were transferred into 24-well plastic culture plates and a total of 1x106 BMSCs 
were placed onto each scaffold. The cells were incubated at 37ºC in 5% CO2 for 7 days and the 
medium changed every 3 days. On day 7, the samples were removed and total RNA isolated using 
Trizol Reagent® (Invitrogen) according to the manufacturer’s instructions. Complementary DNA 
was synthesized from 1 µg of total RNA using SuperScript III reverse transcriptase (Invitrogen) 
following the manufacturer’s instructions. RT-qPCR was performed in 25 µL reaction volume 
containing 12.5 µL 2X SYBR Green Master Mix (Roche, Castle Hill, NSW, Australia), 2.5 µL each 
of 10 µM forward and reverse primers, 2.5 µL of cDNA template diluted 1:10, and 5 µL of RNase 
free water. All samples were performed in triplicates and the house keeping gene, 18s rRNA, was 
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used as a control. The reaction was carried out using ABI Prism 7000 Sequence Detection System 
(Applied Biosystems). Melting curve analysis was performed to validate specific amplicon 
amplification without genomic DNA contamination. Relative expression levels for each gene were 
normalized against the Ct value of the house keeping gene and determined by using the delta Ct 
method. 
 
2.7. Antibiotics loading and release 
As we have found that 2Co-MBG scaffolds have optional viability and VEGF secretion for BMSCs, 
2Co-MBG scaffolds were selected for further drug delivery and in vitro anti-bacteria test. 
2Co-MBG scaffolds (5×5×5 mm) were soaked in 2mL of 5mg/mL of ampicillin-phosphate buffer 
saline (PBS) solution at 4°C overnight. Then the scaffolds were taken out. The ampicillin-PBS 
solution was centrifuged at 10,000 rpm for 10 min and the supernatant were completely removed. 
The loading amount of ampicillin was determined by UV analysis (at wavelength 230nm) through 
calculating the difference of ampicillin-PBS concentration before and after loading. For ampicillin 
releasing test, the collected ampicillin-loaded Co-MBG scaffolds were soaked into 4mL fresh PBS 
at 37°C for different period of time. At each time point, 2mL of PBS solution was taken out to test 
the released ampicillin and 2mL fresh PBS was added back. The accumulative release of ampicillin 
from scaffolds was calculated. 
 
2.8. In vitro anti-bacteria test 
To test the ampicillin release from 2Co-MBG scaffolds on the anti-bacteria effect, one 
ampicillin-loaded scaffold was mixed with 5mL E.coli (DH5α)-LB culture media (3.5-4.0×104 
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bacteria/mL) and maintained at 4°C for 1, 3 and 7 days. Then 10µL of mixture was plated into a 
10mm culture dish and incubated at 37°C for 12 h. The bacteria without scaffolds (blank) or mixed 
with 2Co-MBG scaffolds (without loading with ampicillin) were used as controls. The test was 
carried out in triplicate for each group and the E.coli colonies on each dish were counted for group 
comparisons. 
 
2.9. Statistical analysis 
All data were expressed as means ± standard deviation (SD) and were analyzed using One-Way 
ANOVA with a Post Hoc test. A p-value < 0.05 was considered statistically significant. 
 
3. Results 
3.1. Characterization of porous Co-MBG scaffolds 
SEM analysis showed that the three Co-MBG scaffold types had a highly porous structure with a 
similarly large-pore size ranging roughly from 300 to 500µm (Fig. 1a, c and e). EDS analysis 
showed that Co had been incorporated into the scaffolds. There was no characteristic peak of Co in 
pure the MBG scaffolds (Fig. 1b). The ratio of Co/Ca in the 2Co-MBG and 5Co-MBG scaffolds 
was 0.14 and 0.49, respectively (Fig. 1d and f). Small-angle XRD patterns for the three Co-MBG 
scaffolds types are shown in Figure 2. There are obvious diffraction peaks around 2θ 1.25-1.30 
degree for the MBG, 2Co-MBG and 5Co-MBG scaffolds.  
TEM analysis reveals that both the 2Co-MBG and 5Co-MBG scaffolds have a well-ordered 
mesoporous channel structure (pore size: around 4.5-5nm) (Fig. 3). The results of N2 
adsorption–desorption analysis of the three Co-MBG scaffold types show a type IV isotherm pattern 
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(Fig. 4a) and pore distribution in the range of 4-5 nm (Fig. 4b), a characteristic typical of a 
mesoporous structure. After incorporating 2 and 5% of Co into MBG scaffolds, the specific surface 
area of MBG scaffolds decreased from 290 to 180 and 127 m2/g, respectively, and the pore volume 
decreases from 0.30 to 0.19 and 0.15 cm3/g, respectively (Table 1). The average mesopore size of 
5Co-MBG scaffolds (4.1nm) was observably smaller than that of pure MBG scaffolds (4.97nm). 
 
3.2. Ion release of Co-MBG scaffolds in DMEM 
Generally, the release of Co2+, SiO44- and Ca2+ ions increased commensurate with increased soaking 
time and with a decrease in the concentration of PO43- ions in DMEM (Fig. 5). There is a controlled 
release profile of Co2+ ions, in which high Co-containing MBG scaffolds have a quick release of 
Co2+ ions (Fig. 5a). The incorporation of Co into MBG scaffolds did not significantly change the 
release profile of SiO44- and Ca2+ ions (Fig. 5b and c).  
 
3.3. Attachment, morphology, proliferation and ALP activity of BMSCs on Co-MBG scaffolds 
BMSCs attachment and morphology on the three Co-MBG scaffold types was examined by SEM 
(Fig. 6). After 1 and 7 days of culture, BMSCs were attached to the surface of the pore walls in all 
three scaffolds types (see arrows). Cells have close contact with the scaffolds by numerous 
filopodia.  
MTT analysis shows that cell number increased on the Co-MBG scaffolds with increased culture 
time (Fig. 7a). The proliferation of BMSCs on 2Co-MBG scaffolds showed no difference with that 
of pure MBG scaffolds, whereas cell proliferation on 5Co-MBG scaffolds was slightly less than that 
on 2Co-MBG and pure MBG scaffolds. Overall the cell proliferation on the three scaffold types was 
significantly lower than that on blank control (cell culture plate) (Fig. 7a), which may be attributed 
 13 
to the difference of 3D (scaffolds) and 2D (blank control) culture environment. The ALP activity of 
BMSCs on the three Co-MBG scaffold types showed no obvious differences (p>0.05) and was 
comparable with that of the blank control (Fig. 7b).  
 
3.4. VEGF secretion, bone-relative gene and HIF-1α expression of BMSCs on Co-MBG scaffolds 
Incorporating 2% of Co into MBG scaffolds significantly enhances the VEGF secretion of BMSCs 
at day 7 (Fig. 8). HIF-1α expression of BMSCs in Co-MBG scaffolds also increased with increased 
Co contents (Fig. 9). Interestingly, both 2Co-MBG and 5Co-MBG scaffolds have significantly 
enhanced bone-related gene expression of VEGF at day 7, compared to pure MBG scaffolds and the 
blank control (Fig. 10a). OCN expression of BMSCs on 5Co-MBG scaffolds was upregulated 
compared to pure MBG scaffolds and the blank controls (Fig. 10b). 
 
3.5. Antibiotics release and in vitro anti-bacteria test 
2Co-MBG scaffolds showed a sustained release of ampicillin over the initial 72 h and the release 
then plateaued (Fig. 11a). Bacterial survival rate fell significantly in the ampicillin loaded scaffolds 
compared to blank controls and non-ampicillin loaded scaffolds (Fig. 11b). 
 
4. Discussion 
In this study, we have successfully prepared hypoxia-mimicking MBG scaffolds with hierarchically 
large pores (300-500µm) and well-ordered mesopores (5nm) by incorporating Co2+ ions into the 
scaffolds. We further investigated the effects of Co on the proliferation, differentiation, VEGF 
secretion, HIF-1α expression, and bone-related gene expression of BMSCs in MBG scaffolds. Our 
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results show that the incorporation of Co2+ ions into MBG scaffolds is a viable way to enhance 
VEGF secretion, HIF-1α expression, and bone-related gene expression of BMSCs; the prepared 
Co-MBG scaffolds had an obvious hypoxia inducing function. In addition to these properties, the 
Co-MBG scaffolds had well-ordered mesopore channel structures, making them well-suited to 
efficiently load and release antibiotics drugs; the sustained release of antibiotics from the scaffolds 
adds an anti-bacterial feature. These results suggest that these hypoxia-mimicking MBG scaffolds 
combine angiogenesis with osteogenesis, as well as an anti-bacterial function for bone tissue 
engineering applications. 
Co-MBG scaffolds were prepared by a typical polymer sponge method, in which some fraction of 
the Ca in the scaffolds was substituted by Co. This resulted in the advantage of the Co-MBG 
scaffolds having a sustained release of Co2+ ions into the liquid medium; the amount released 
depending on the amount of Co incorporated into the scaffolds in the first place. Previous studies 
have indicated that cobalt at high concentrations of may cause cell toxicity [32-34]. A controlled ion 
release system is therefore vital for tissue engineering applications for vascularized bone 
regeneration. With this in mind, in the current study the Co-MBG scaffold system had to satisfy the 
requirement that the Co2+ ions had to have a controlled release by only loading limited amounts of 
Co into the scaffolds. Our results have shown that the concentration of the released Co2+ ions from 
2Co-MBG and 5Co-MBG scaffolds did not exceed 20 ppm, a relatively low concentration. For this 
reason, we found that the manufactured Co-MBG scaffolds supported the attachment and growth of 
BMSCs, with no obvious cytotoxicity. It did appear, however, that 5% Co did have the effect of 
reducing BMSC viability. Incorporating ionic Co into the MBG scaffolds at 2 and 5% did not affect 
ALP activity of BMSCs; ALP is an early cell differentiation marker. Our results, therefore, suggests 
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that Co-MBG scaffolds with Co contents less than 5% can support the normal differentiation of 
BMSCs with no obvious cytotoxic effects. 
It was most encouraging that incorporating Co into MBG scaffolds did, in fact, induce a significant 
hypoxic cascade, including increased VEGF protein secretion, HIF-1α and VEGF gene expression 
in BMSCs. Anginogenesis is directed by a variety of growth factors in a complex multistep process, 
in which VEGF has been identified as a key regulator [35,36]. VEGF activates endothelial cells in 
the surrounding tissue by stimulating their liberation, migration, proliferation, and finally the 
formation of tubular structures [37]. HIF-1α can initiate the expression of a number of genes 
associated with tissue regeneration and skeletal tissue development which are activated in fracture 
repair [13]. The incorporation of ionic Co into MBG scaffolds has scientific merit and is a 
promising strategy with which to induce the hypoxic cascade to promote neovascularization of 
scaffolds for bone tissue regeneration. Previous studies have demonstrated that Co2+ ions are a 
chemical inducer of HIF-1α that triggers a hypoxia-like response by causing an oxygen deficient 
microenvironment [12]. Under conditions of normal oxygen tension (normoxia) HIF-1α is degraded 
by ubiquitination in the proteasome, although it is constitutively expressed. In hypoxic conditions, 
HIF-1α is stabilized due to the lack of oxygen, and binds to DNA at a specific recognition of target 
genes. Although oxygen is present in normoxic conditions, Co ions can inactivate HIF-specific 
prolyl hydroxylases leading to the stabilization of HIF-1α, therefore, mimicking hypoxia conditions 
[26]. There are few reports as to whether Co2+ ion incorporation into tissue engineering scaffolds is 
capable of inducing a hypoxic response. Our study does indicate the induction of hypoxic functions 
is possible by doping Co2+ ions into biomaterials. We are of the view that this is an important study 
as it paves the way to prepare functional biomaterials with improved anginogenesis and 
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osteogenesis capacity.  
In bone reconstruction surgery, osteomyelitis caused by bacterial infection is an everpresent and 
serious complication. Conventional treatments include systemic antibiotic administration, surgical 
debridement, wound drainage and implant removal [38]. These approaches are, however, rather 
inefficient and results in additional surgical interventions for the patient. A new method to solve this 
problem is to introduce system of local drug release system into the implant site. The advantages of 
this treatment include high delivery efficiency, continuous action, reduced toxicity and convenience 
to the patients [38,39]. A 3D scaffold with an in-built drug delivery property would be very useful 
for bone tissue regeneration and can solve the risk of osteomyelitis incidences caused by infection 
of the bone. The incorporation of Co into the MBG scaffolds decreased the specific surface area and 
nano-pore volume. The likely cause of this may be due to the fact that replacing Ca2+ with Co2+ may 
somehow disrupt the ordered orientation of mesopore channels during the self-assembly reaction. 
However, the manufactured Co-MBG scaffolds still maintained well-ordered mesoporous structures, 
as well as a high surface area and nanopore volume, all of which are important for the loading and 
delivery of drugs [31,40,41]. The results from this study suggest that Co-MBG scaffolds are capable 
of being efficiently loaded with an antibiotics drug and then subsequently deliver that drug topically 
at the site of implant. Co-MBG scaffolds, therefore, have potential as a local drug delivery system 
with functional anti-bacterial effect for bone tissue engineering. 
 
5. Conclusions 
Hypoxia-mimicking MBG scaffolds with hierarchically large pores (300-500µm) and well-ordered 
mesopores (5nm) were successfully prepared by substituting parts of the Ca2+ ions for Co2+ ions in 
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the scaffolds. The prepared Co-MBG scaffolds significantly enhance VEGF protein secretion, 
HIF-1α expression, and bone-related gene expression of BMSCs, compared to pure MBG scaffolds. 
The incorporation of Co2+ ions into MBG scaffolds is an efficient way to induce the hypoxic 
cascade. The mesopore structure of the Co-MBG scaffolds gives them capacity for sustained release 
of antibiotics drug and, therefore, had considerable anti-bacterial properties. The study confirms 
that the application of the hypoxia concept to the tissue engineering scaffolds is possible. The 
hypoxia-mimicking MBG scaffolds have potential uses in bone tissue engineering applications as a 
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